122 related articles for article (PubMed ID: 26524858)
41. Extensive alternative splicing of the repressor element silencing transcription factor linked to cancer.
Chen GL; Miller GM
PLoS One; 2013; 8(4):e62217. PubMed ID: 23614038
[TBL] [Abstract][Full Text] [Related]
42. A statistical framework for genome-wide discovery of biomarker splice variations with GeneChip Human Exon 1.0 ST Arrays.
Yoshida R; Numata K; Imoto S; Nagasaki M; Doi A; Ueno K; Miyano S
Genome Inform; 2006; 17(1):88-99. PubMed ID: 17503359
[TBL] [Abstract][Full Text] [Related]
43. The second RNA-binding domain of the human splicing factor ASF/SF2 is the critical domain controlling adenovirus E1A alternative 5'-splice site selection.
Dauksaite V; Akusjärvi G
Biochem J; 2004 Jul; 381(Pt 2):343-50. PubMed ID: 15068396
[TBL] [Abstract][Full Text] [Related]
44. RBFOX2 protein domains and cellular activities.
Arya AD; Wilson DI; Baralle D; Raponi M
Biochem Soc Trans; 2014 Aug; 42(4):1180-3. PubMed ID: 25110022
[TBL] [Abstract][Full Text] [Related]
45. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
Lukas J; Gao DQ; Keshmeshian M; Wen WH; Tsao-Wei D; Rosenberg S; Press MF
Cancer Res; 2001 Apr; 61(7):3212-9. PubMed ID: 11306511
[TBL] [Abstract][Full Text] [Related]
46. Alternative splicing in protein associated with Myc (Pam) influences its binding to c-Myc.
Santos TM; Han S; Bowser M; Sazani K; Beauchamp RL; Murthy V; Bhide PG; Ramesh V
J Neurosci Res; 2006 Feb; 83(2):222-32. PubMed ID: 16342205
[TBL] [Abstract][Full Text] [Related]
47. Evidence that "brain-specific" FOX-1, FOX-2, and nPTB alternatively spliced isoforms are produced in the lens.
Bitel CL; Nathan R; Wong P; Kuppasani S; Matsushita M; Kanazawa H; Frederikse PH
Curr Eye Res; 2011 Apr; 36(4):321-7. PubMed ID: 21714144
[TBL] [Abstract][Full Text] [Related]
48. New discoveries of old SON: a link between RNA splicing and cancer.
Hickey CJ; Kim JH; Ahn EY
J Cell Biochem; 2014 Feb; 115(2):224-31. PubMed ID: 24030980
[TBL] [Abstract][Full Text] [Related]
49. Identification of recurrent regulated alternative splicing events across human solid tumors.
Danan-Gotthold M; Golan-Gerstl R; Eisenberg E; Meir K; Karni R; Levanon EY
Nucleic Acids Res; 2015 May; 43(10):5130-44. PubMed ID: 25908786
[TBL] [Abstract][Full Text] [Related]
50. Alternative splicing regulation by Muscleblind proteins: from development to disease.
Fernandez-Costa JM; Llamusi MB; Garcia-Lopez A; Artero R
Biol Rev Camb Philos Soc; 2011 Nov; 86(4):947-58. PubMed ID: 21489124
[TBL] [Abstract][Full Text] [Related]
51. Alternative RNA splicing defects in pediatric cancers: new insights in tumorigenesis and potential therapeutic vulnerabilities.
Venkataramany AS; Schieffer KM; Lee K; Cottrell CE; Wang PY; Mardis ER; Cripe TP; Chandler DS
Ann Oncol; 2022 Jun; 33(6):578-592. PubMed ID: 35339647
[TBL] [Abstract][Full Text] [Related]
52. RBFOX2 is an important regulator of mesenchymal tissue-specific splicing in both normal and cancer tissues.
Venables JP; Brosseau JP; Gadea G; Klinck R; Prinos P; Beaulieu JF; Lapointe E; Durand M; Thibault P; Tremblay K; Rousset F; Tazi J; Abou Elela S; Chabot B
Mol Cell Biol; 2013 Jan; 33(2):396-405. PubMed ID: 23149937
[TBL] [Abstract][Full Text] [Related]
53. Alternative splicing in cancers: From aberrant regulation to new therapeutics.
Song X; Zeng Z; Wei H; Wang Z
Semin Cell Dev Biol; 2018 Mar; 75():13-22. PubMed ID: 28919308
[TBL] [Abstract][Full Text] [Related]
54. RBFOX2 and alternative splicing in B-cell lymphoma.
Quentmeier H; Pommerenke C; Bernhart SH; Dirks WG; Hauer V; Hoffmann S; Nagel S; Siebert R; Uphoff CC; Zaborski M; Drexler HG;
Blood Cancer J; 2018 Aug; 8(8):77. PubMed ID: 30097561
[No Abstract] [Full Text] [Related]
55. MYC regulates a pan-cancer network of co-expressed oncogenic splicing factors.
Urbanski L; Brugiolo M; Park S; Angarola BL; Leclair NK; Yurieva M; Palmer P; Sahu SK; Anczuków O
Cell Rep; 2022 Nov; 41(8):111704. PubMed ID: 36417849
[TBL] [Abstract][Full Text] [Related]
56. High-throughput alternative splicing detection using dually constrained correspondence analysis (DCCA).
Baty F; Klingbiel D; Zappa F; Brutsche M
J Biomed Inform; 2015 Dec; 58():175-185. PubMed ID: 26483173
[TBL] [Abstract][Full Text] [Related]
57. Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer.
Cieśla M; Ngoc PCT; Cordero E; Martinez ÁS; Morsing M; Muthukumar S; Beneventi G; Madej M; Munita R; Jönsson T; Lövgren K; Ebbesson A; Nodin B; Hedenfalk I; Jirström K; Vallon-Christersson J; Honeth G; Staaf J; Incarnato D; Pietras K; Bosch A; Bellodi C
Mol Cell; 2021 Apr; 81(7):1453-1468.e12. PubMed ID: 33662273
[TBL] [Abstract][Full Text] [Related]
58. Alternative splicing variant of NRP/B promotes tumorigenesis of gastric cancer.
Kim A; Mok BR; Hahn S; Yoo J; Kim DH; Kim TA
BMB Rep; 2022 Jul; 55(7):348-353. PubMed ID: 35725010
[TBL] [Abstract][Full Text] [Related]
59. Point-of-care testing in the diagnosis of gastrointestinal cancers: current technology and future directions.
Huddy JR; Ni MZ; Markar SR; Hanna GB
World J Gastroenterol; 2015 Apr; 21(14):4111-20. PubMed ID: 25892860
[TBL] [Abstract][Full Text] [Related]
60. The master regulator FUBP1: its emerging role in normal cell function and malignant development.
Debaize L; Troadec MB
Cell Mol Life Sci; 2019 Jan; 76(2):259-281. PubMed ID: 30343319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
